Literature DB >> 8214955

Epidemiology of beryllium sensitization and disease in nuclear workers.

K Kreiss1, M M Mroz, B Zhen, J W Martyny, L S Newman.   

Abstract

We examined the epidemiology of chronic beryllium disease among a stratified, random sample (n = 895) of nuclear weapons workers using the blood beryllium lymphocyte transformation (BeLT) test and chest radiograph for case identification. Of 18 new cases of beryllium sensitization, 12 had beryllium disease, and three more developed pulmonary granulomas on lung biopsy over the succeeding 2 yr. Beryllium-sensitized cases did not differ from noncases in age, gender, race, ethnicity, smoking, most respiratory symptoms, spirometric or radiographic abnormalities, or job tenure. The six sensitized cases without initial disease differed from beryllium disease cases in having greater pack-years of smoking. Sensitization occurred among workers with inadvertent or bystander exposure, such as a secretary and security guard. However, beryllium sensitization risk was higher for machinists (4.7%) and for persons reporting measured overexposure (7.4%, odds ratio 5.1); exposure beginning before 1970 (3.6%, odds ratio 2.7); consistent beryllium exposure (3.4%); and sawing (4.7%) or band sawing (6.0%) of beryllium metal. We conclude that both individual susceptibility to sensitization and exposure circumstances are important in developing disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214955     DOI: 10.1164/ajrccm/148.4_Pt_1.985

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  44 in total

Review 1.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

Review 3.  The role of lymphocyte proliferation tests in assessing occupational sensitization and disease.

Authors:  Stella E Hines; Karin Pacheco; Lisa A Maier
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-04

4.  Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant.

Authors:  K Kreiss; M M Mroz; B Zhen; H Wiedemann; B Barna
Journal:  Occup Environ Med       Date:  1997-08       Impact factor: 4.402

5.  Beryllium's public relations problem: protecting workers when there is no safe exposure level.

Authors:  David Michaels; Celeste Monforton
Journal:  Public Health Rep       Date:  2008 Jan-Feb       Impact factor: 2.792

6.  Crystal structure of HLA-DP2 and implications for chronic beryllium disease.

Authors:  Shaodong Dai; Guinevere A Murphy; Frances Crawford; Douglas G Mack; Michael T Falta; Philippa Marrack; John W Kappler; Andrew P Fontenot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-31       Impact factor: 11.205

7.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

8.  Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.

Authors:  Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

9.  The uses and adverse effects of beryllium on health.

Authors:  Ross G Cooper; Adrian P Harrison
Journal:  Indian J Occup Environ Med       Date:  2009-08

10.  Long-term follow-up of beryllium sensitized workers from a single employer.

Authors:  Mona Duggal; David C Deubner; Anne M Curtis; Mark R Cullen
Journal:  BMC Public Health       Date:  2010-01-04       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.